| King David Nursing And Rehabilitation Center | |
| 4204 Old Milford Mill Road, Baltimore, Maryland 21208 | |
| (410) 486-1500 | |
| Name | King David Nursing And Rehabilitation Center |
|---|---|
| Location | 4204 Old Milford Mill Road, Baltimore, Maryland |
| Certified By | Medicare and Medicaid |
| No. of Certified Beds | 100 |
| Occupancy Rate | 88.6% |
| Medicare ID (CCN) | 215022 |
| Legal Business Name | King David At Autumn Lake Llc |
| Ownership Type | For Profit - Partnership |
| NPI Number | 1295726149 |
| Organization Name | MILFORD MANOR CORPORATION |
| Doing Business As | MILFORD MANOR NURSING & REHABILITATION CENTER |
| Address | 4204 Old Milford Mill Rd, Pikesville, MD 21208 |
| Phone Number | 410-486-1500 |
News Archive
According to physicians familiar with the investigation, the causes of the "mystery illness" that has killed more than 60 children in Cambodia have been identified, CNN reports. "A combination of pathogens ... is to blame for the illness, the World Health Organization, in conjunction with the Cambodian Ministry of Health, has concluded, the doctors said," according to the news service.
Elsevier, a global research publishing and information analytics provider, recently launched the English version of COVID-19: The Essentials of Prevention and Treatment. A digital version of the book is freely available to download on Elsevier's Novel Coronavirus Information Center here.
The U.S. Food and Drug Administration today approved Ampyra (dalfampridine) extended release tablets to improve walking in patients with multiple sclerosis (MS). In clinical trials, patients treated with Ampyra had faster walking speeds than those treated with an inactive pill (placebo). This is the first drug approved for this use.
The use of acid-suppressing medications or antibiotics in the first 6 months of infancy was associated with an increased risk for the subsequent development of allergic diseases in childhood.
› Verified 9 days ago
| NPI Number | 1437693785 |
| Organization Name | KING DAVID AT AUTUMN LAKE LLC |
| Doing Business As | KING DAVID NURSING AND REHABILITATION CENTER |
| Address | 4204 Old Milford Mill Rd, Baltimore, MD 21208 |
| Phone Number | 410-486-1500 |
News Archive
According to physicians familiar with the investigation, the causes of the "mystery illness" that has killed more than 60 children in Cambodia have been identified, CNN reports. "A combination of pathogens ... is to blame for the illness, the World Health Organization, in conjunction with the Cambodian Ministry of Health, has concluded, the doctors said," according to the news service.
Elsevier, a global research publishing and information analytics provider, recently launched the English version of COVID-19: The Essentials of Prevention and Treatment. A digital version of the book is freely available to download on Elsevier's Novel Coronavirus Information Center here.
The U.S. Food and Drug Administration today approved Ampyra (dalfampridine) extended release tablets to improve walking in patients with multiple sclerosis (MS). In clinical trials, patients treated with Ampyra had faster walking speeds than those treated with an inactive pill (placebo). This is the first drug approved for this use.
The use of acid-suppressing medications or antibiotics in the first 6 months of infancy was associated with an increased risk for the subsequent development of allergic diseases in childhood.
› Verified 9 days ago
| NPI Number | 1497222830 |
| Organization Name | KING DAVID AT AUTUMN LAKE LLC |
| Address | 4204 Old Milford Mill Rd, Pikesville, MD 21208 |
| Phone Number | 410-486-1500 |
News Archive
According to physicians familiar with the investigation, the causes of the "mystery illness" that has killed more than 60 children in Cambodia have been identified, CNN reports. "A combination of pathogens ... is to blame for the illness, the World Health Organization, in conjunction with the Cambodian Ministry of Health, has concluded, the doctors said," according to the news service.
Elsevier, a global research publishing and information analytics provider, recently launched the English version of COVID-19: The Essentials of Prevention and Treatment. A digital version of the book is freely available to download on Elsevier's Novel Coronavirus Information Center here.
The U.S. Food and Drug Administration today approved Ampyra (dalfampridine) extended release tablets to improve walking in patients with multiple sclerosis (MS). In clinical trials, patients treated with Ampyra had faster walking speeds than those treated with an inactive pill (placebo). This is the first drug approved for this use.
The use of acid-suppressing medications or antibiotics in the first 6 months of infancy was associated with an increased risk for the subsequent development of allergic diseases in childhood.
› Verified 9 days ago
| Ratings from Surveys (Inspections): | |
| Ratings from Quality Measures: | |
| Ratings from Staffing Data: | |
| Overall Rating: |
|---|
News Archive
According to physicians familiar with the investigation, the causes of the "mystery illness" that has killed more than 60 children in Cambodia have been identified, CNN reports. "A combination of pathogens ... is to blame for the illness, the World Health Organization, in conjunction with the Cambodian Ministry of Health, has concluded, the doctors said," according to the news service.
Elsevier, a global research publishing and information analytics provider, recently launched the English version of COVID-19: The Essentials of Prevention and Treatment. A digital version of the book is freely available to download on Elsevier's Novel Coronavirus Information Center here.
The U.S. Food and Drug Administration today approved Ampyra (dalfampridine) extended release tablets to improve walking in patients with multiple sclerosis (MS). In clinical trials, patients treated with Ampyra had faster walking speeds than those treated with an inactive pill (placebo). This is the first drug approved for this use.
The use of acid-suppressing medications or antibiotics in the first 6 months of infancy was associated with an increased risk for the subsequent development of allergic diseases in childhood.
› Verified 9 days ago
| Number of Facility Reported Incidents | 0 |
| Number of Substantiated Complaints | 0 |
| Number of Fines | 0 |
| Total Amount of Fines in Dollars | $0 |
| Number of Payment Denials | 0 |
| Total Number of Penalties | 0 |
| Experience Measure | Provider | National Avg. |
|---|---|---|
| Percentage of long-stay residents whose need for help with daily activities has increased | 27.05 | 14.46 |
| Percentage of long-stay residents who lose too much weight | 19.27 | 5.51 |
| Percentage of low risk long-stay residents who lose control of their bowels or bladder | 79.31 | 48.41 |
| Percentage of long-stay residents with a catheter inserted and left in their bladder | 0 | 1.79 |
| Percentage of long-stay residents with a urinary tract infection | 1 | 2.65 |
| Percentage of long-stay residents who have depressive symptoms | 28.48 | 5.05 |
| Percentage of long-stay residents who were physically restrained | 0 | 0.23 |
| Percentage of long-stay residents experiencing one or more falls with major injury | 5.22 | 3.36 |
| Percentage of long-stay residents assessed and appropriately given the pneumococcal vaccine | 92.17 | 93.87 |
| Percentage of long-stay residents who received an antipsychotic medication | 14.93 | 14.2 |
| Percentage of short-stay residents assessed and appropriately given the pneumococcal vaccine | 55.6 | 83.88 |
| Percentage of short-stay residents who newly received an antipsychotic medication | 2.69 | 1.79 |
| Percentage of long-stay residents whose ability to move independently worsened | 49.96 | 17.09 |
| Percentage of long-stay residents who received an antianxiety or hypnotic medication | 13.12 | 19.7 |
| Percentage of high risk long-stay residents with pressure ulcers | 13.04 | 7.32 |
| Percentage of long-stay residents assessed and appropriately given the seasonal influenza vaccine | 97.46 | 95.98 |
| Percentage of short-stay residents who made improvements in function | 77.55 | 67.99 |
| Percentage of short-stay residents who were assessed and appropriately given the seasonal influenza vaccine | 67.33 | 82.93 |
News Archive
According to physicians familiar with the investigation, the causes of the "mystery illness" that has killed more than 60 children in Cambodia have been identified, CNN reports. "A combination of pathogens ... is to blame for the illness, the World Health Organization, in conjunction with the Cambodian Ministry of Health, has concluded, the doctors said," according to the news service.
Elsevier, a global research publishing and information analytics provider, recently launched the English version of COVID-19: The Essentials of Prevention and Treatment. A digital version of the book is freely available to download on Elsevier's Novel Coronavirus Information Center here.
The U.S. Food and Drug Administration today approved Ampyra (dalfampridine) extended release tablets to improve walking in patients with multiple sclerosis (MS). In clinical trials, patients treated with Ampyra had faster walking speeds than those treated with an inactive pill (placebo). This is the first drug approved for this use.
The use of acid-suppressing medications or antibiotics in the first 6 months of infancy was associated with an increased risk for the subsequent development of allergic diseases in childhood.
› Verified 9 days ago
King David Nursing And Rehabilitation Center Location: 4204 Old Milford Mill Road, Baltimore, Maryland 21208 Phone: (410) 486-1500 | |
Autumn Lake Healthcare At Long Green Location: 115 East Melrose Avenue, Baltimore, Maryland 21212 Phone: (410) 435-9073 | |
Levindale Hebrew Ger Ctr & Hsp Location: 2434 W. Belvedere Avenue, Baltimore, Maryland 21215 Phone: (410) 466-8700 | |
Keswick Multi-care Center Location: 700 West 40th Street, Baltimore, Maryland 21211 Phone: (410) 235-8860 | |
St. Elizabeth Rehab. & Nsg. Ce Location: 3320 Benson Avenue, Baltimore, Maryland 21227 Phone: (667) 600-2600 | |
Autumn Lake Healthcare At Homewood Location: 6000 Bellona Avenue, Baltimore, Maryland 21212 Phone: (410) 323-4223 |